An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab

The purpose of this study is to assess the safety and tumor-shrinking ability of experimental medication BMS-986179 alone and when combined with Nivolumab, in patients with solid cancers that are advanced or have spread.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02754141.

Trial PhasePhase I/II

Trial Typetreatment

Lead OrganizationBristol-Myers Squibb

• Primary IDCA013-004
• Secondary IDsNCI-2016-01162, 2016-000603-91
• ClinicalTrials.gov IDNCT02754141